Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

@article{Wang2013TargetingBW,
  title={Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.},
  author={Michael L. Wang and Simon A. Rule and Peter Martin and Andre H Goy and Rebecca L. Auer and Brad S. Kahl and Wojciech Jurczak and Ranjana H. Advani and Jorge E Romaguera and Michael E. Williams and Jacqueline C. Barrientos and Ewa Chmielowska and John A. Radford and Stephan Stilgenbauer and Martin Dreyling and Wiesław Wiktor Jędrzejczak and Peter W M Johnson and Stephen E Spurgeon and Lei Li and Liang Zhang and Kate Juliet Newberry and Zhishuo Ou and Nancy Cheng and Bingliang Fang and Jesse S. McGreivy and Fong Clow and Joseph J. Buggy and Betty Y. Chang and Darrin M. Beaupre and Lori A. Kunkel and Kristie A. Blum},
  journal={The New England journal of medicine},
  year={2013},
  volume={369 6},
  pages={
          507-16
        }
}
BACKGROUND Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma. METHODS In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma. Patients were enrolled into two groups… 

Figures and Tables from this paper

BTK inhibitor ibrutinib in CLL and mantle cell lymphoma

Ibrutinib treatment was found to produce high rates of durable responses in patients with relapsed or refractory CLL or small lymphocytic lymphoma, independent of baseline clinical and genomic risk factors, including advanced-stage disease, number of previous therapies, and the 17p13.1 deletion.

Ibrutinib for the Treatment of Mantle Cell Lymphoma

Ibrutinib's response rate and duration of response compare favorably with those for other novel agents approved for the treatment of relapsed or refractory MCL, while being less toxic than most chemotherapy or chemoimmunotherapy regimens.

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

Single-agent ibrutinib induced durable responses with a favorable benefit-risk profile in patients with previously treated MZL, confirming the role of BCR signaling in this malignancy.

Ibrutinib in B-cell Lymphomas

Ibrutinib is an oral therapy taken daily that has been well tolerated by patients and is now being evaluated in combination therapy both in relapsed B-cell malignancies and frontline studies in DLBCL and MCL.

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors

The current evidence for the available treatment of R/R MCL after progression on Bruton’s tyrosine kinase inhibitors (BTKi) is described and certain therapies, such as chimeric antigen receptor (CAR) T cells, have shown promising results after BTKi failure.

Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

These results demonstrate high and durable ORR and CR rates in patients with relapsed/refractory MCL and Zanubrutinib was generally well tolerated; grade ≥3 BTK inhibitor-associated toxicities were uncommon.

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.

Ibrutinib is a well-tolerated treatment with modest activity in relapsed FL and Evaluation of BTK inhibitors in earlier lines of therapy may be warranted on the basis of improved response rates in rituximab-sensitive disease.

Ibrutinib: A Review of Its Use in Patients with Mantle Cell Lymphoma or Chronic Lymphocytic Leukaemia

Given its efficacy and tolerability, once-daily, oral ibrutinib is an emerging treatment option for patients with relapsed/refractory MCL or CLL and CLL patients with del 17p or TP53 mutation.

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia

  • D. TuckerS. Rule
  • Medicine, Biology
    Therapeutics and clinical risk management
  • 2015
The currently available data on safety and efficacy from clinical trials of ibrutinib in the management of MCL and CLL, both as a single agent and in combination with other therapies, are appraised and how this drug is likely to be used in future clinical practice is considered.
...

References

SHOWING 1-10 OF 35 REFERENCES

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

  • R. FisherS. Bernstein A. Goy
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
Bortezomib provides significant clinical activity in terms of durable and complete responses, and may represent a new treatment option for this population with usually very poor outcome.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

  • R. AdvaniJ. Buggy N. Fowler
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
Ibrutinib, a novel BTK-targeting inhibitor, is well tolerated, with substantial activity across B-cell histologies, consistent with the irreversible mechanism.

Novel targeted therapies for mantle cell lymphoma

It is reported that milatuzumab, a fully humanized anti-CD74 monoclonal antibody (mAb), in combination with anti- CD20 mAbs has significant preclinical and clinical activity in MCL, and preliminary data on the activity of other targeted biologic agents are reported.

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

  • G. HessR. Herbrecht B. Coiffier
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
Temsirolimus 175 mg weekly for 3 weeks followed by 75 mg weekly significantly improved PFS and objective response rate compared with investigator's choice therapy in patients with relapsed or refractory MCL.

Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.

  • A. Wiestner
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
An overview of the role of BTK for B-cell receptor (BCR) signaling and the importance of the BCR in B- cell malignancies is provided and the results of the first clinical study of ibrutinib in patients with relapsed/refractory B- Cell malignancy are presented.

Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma.

  • J. VoseV. Sneller
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2003
The objectives of the study were to determine the chemosensitivity rate in patients with recurrent or refractory NHL treated with ICE in combination with rituximab (R-ICE) and to determine whether ritUXimab changes the toxicity profile of ICE chemotherapy regimen in these patients.

Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin’s lymphoma

The objectives of the study were to determine the chemosensitivity rate in patients with recurrent or refractory NHL treated with ICE in combination with rituximab (R-ICE) and to determine whether ritUXimab changes the toxicity profile of ICE chemotherapy regimen in these patients.

Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

It is concluded that intense chemoimmunotherapy without stem cell transplantation is effective for untreated aggressive MCL.